Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Irinotecan Based on UGT1A1 Genotype in Locally Advanced Colon Cancer
NCT01826396Phase 2Unknown
- Sponsor
- Colorectal Cancer Institute of Heilongjiang Academy of Medical Sciences
- Start
- Apr 2013
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in colon cancer, sponsored by Colorectal Cancer Institute of Heilongjiang Academy of Medical Sciences. Primary endpoint: R0 Resection Rate at 1 year. Status: unknown.
02
Drugs
irinotecan
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT01826396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01826396.